|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clini. 69:7–34. 2019. View Article : Google Scholar
|
|
2
|
Sorosky JI: Endometrial cancer. Obstet
Gynecol. 120:383–397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Salvesen HB, Haldorsen IS and Trovik J:
Markers for individualised therapy in endometrial carcinoma. Lancet
Oncol. 13:e353–e361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dedes KJ, Wetterskog D, Ashworth A, Kaye
SB and Reis-Filho JS: Emerging therapeutic targets in endometrial
cancer. Nature reviews Clin Oncol. 8:261–271. 2011. View Article : Google Scholar
|
|
5
|
Gressel GM, Parkash V and Pal L:
Management options and fertility-preserving therapy for
premenopausal endometrial hyperplasia and early-stage endometrial
cancer. Int J Gynaecol Obstet. 131:234–239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brooks RA, Fleming GF, Lastra RR, Lee NK,
Moroney JW, Son CH, Tatebe K and Veneris JL: Current
recommendations and recent progress in endometrial cancer. CA
Cancer J Clin. 69:258–279. 2019.PubMed/NCBI
|
|
7
|
Wang D, Zheng W, Wang SM, Wang JB, Wei WQ,
Liang H, Qiao YL and Boffetta P: Estimation of cancer incidence and
mortality attributable to overweight, obesity, and physical
inactivity in China. Nutr Cancer. 64:48–56. 2012. View Article : Google Scholar
|
|
8
|
Lee YC, Lheureux S and Oza AM: Treatment
strategies for endometrial cancer: Current practice and
perspective. Curr Opin Obstet Gynecol. 29:47–58. 2017. View Article : Google Scholar
|
|
9
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lax SF, Kendall B, Tashiro H, Slebos RJ
and Hedrick L: The frequency of p53, K-ras mutations, and
microsatellite instability differs in uterine endometrioid and
serous carcinoma: Evidence of distinct molecular genetic pathways.
Cancer. 88:814–824. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Norimatsu Y, Ohsaki H, Yanoh K, Kawanishi
N and Kobayashi TK: Expression of immunoreactivity of nuclear
findings by p53 and cyclin a in endometrial cytology: Comparison
with endometrial glandular and stromal breakdown and endometrioid
adenocarcinoma grade 1. Diagn Cytopathol. 41:303–307. 2013.
View Article : Google Scholar
|
|
12
|
Yan C, Lu D, Hai T and Boyd DD: Activating
transcription factor 3, a stress sensor, activates p53 by blocking
its ubiquitination. EMBO J. 24:2425–2435. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei S, Wang H, Lu C, Malmut S, Zhang J,
Ren S, Yu G, Wang W, Tang DD and Yan C: The activating
transcription factor 3 protein suppresses the oncogenic function of
mutant p53 proteins. J Biol Chem. 289:8947–8959. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Corrigendum to 'Revised FIGO staging for
carcinoma of the cervix uteri' (Int J Gynecol Obstet 145(2019)
129-135). Int J Gynecol Obstet. 147:279–280. 2019. View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
16
|
Song HM, Park GH, Eo HJ and Jeong JB:
Naringenin-mediated ATF3 expression contributes to apoptosis in
human colon cancer. Biomol Ther (Seoul). 24:140–146. 2016.
View Article : Google Scholar
|
|
17
|
Wu ZY, Wei ZM, Sun SJ, Yuan J and Jiao SC:
Activating transcription factor 3 promotes colon cancer metastasis.
Tumour Biol. 35:8329–8334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li X, Zhou X, Li Y, Zu L, Pan H, Liu B,
Shen W, Fan Y and Zhou Q: Activating transcription factor 3
promotes malignance of lung cancer cells in vitro. Thorac Cancer.
8:181–191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan TJ, Han LH, Cong RS and Liang J:
Caspase family proteases and apoptosis. Acta Biochim Biophys Sin
(Shanghai). 37:719–727. 2005. View Article : Google Scholar
|
|
20
|
Inoue M, Uchida Y, Edagawa M, Hirata M,
Mitamura J, Miyamoto D, Taketani K, Sekine S, Kawauchi J and
Kitajima S: The stress response gene ATF3 is a direct target of the
Wnt/β-catenin pathway and inhibits the invasion and migration of
HCT116 human colorectal cancer cells. PLoS One. 13:e01941602018.
View Article : Google Scholar
|
|
21
|
Guenzle J, Wolf LJ, Garrelfs NW, Goeldner
JM, Osterberg N, Schindler CR, Saavedra JE and Weyerbrock A: ATF3
reduces migration capacity by regulation of matrix
metalloproteinases via NFkappaB and STAT3 inhibition in
glioblastoma. Cell Death Discov. 3:170062017. View Article : Google Scholar
|
|
22
|
Yang HK, Jeong KC, Kim YK and Jung ST:
Role of matrix metalloproteinase (MMP) 2 and MMP-9 in soft tissue
sarcoma. Clin Orthop Surg. 6:443–454. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jujo T, Sakao S, Tsukahara M, Kantake M,
Maruoka M, Tanabe N, Masuda M and Tatsumi K: The role of matrix
metalloproteinase in the intimal sarcoma-like cells derived from
endarterectomized tissues from a chronic thromboembolic pulmonary
hypertension patient. PLoS One. 9:e874892014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Clark IM, Swingler TE, Sampieri CL and
Edwards DR: The regulation of matrix metalloproteinases and their
inhibitors. Int J Biochem Cell Biol. 40:1362–1378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Page-McCaw A, Ewald AJ and Werb Z: Matrix
metalloproteinases and the regulation of tissue remodelling. Nature
reviews Mol Cell Biol. 8:221–233. 2007. View Article : Google Scholar
|
|
26
|
Wang Z, Kim J, Teng Y, Ding HF, Zhang J,
Hai T, Cowell JK and Yan C: Loss of ATF3 promotes hormone-induced
prostate carcinogenesis and the emergence of CK5(+)CK8(+)
epithelial cells. Oncogene. 35:3555–3564. 2016. View Article : Google Scholar
|
|
27
|
Papoudou-Bai A, Goussia A, Batistatou A,
Stefanou D, Malamou-Mitsi V and Kanavaros P: The expression levels
of JunB, JunD and p-c-Jun are positively correlated with tumor cell
proliferation in diffuse large B-cell lymphomas. Leuk Lymphoma.
57:143–150. 2016. View Article : Google Scholar
|
|
28
|
Bamberger AM, Milde-Langosch K, Rossing E,
Goemann C and Loning T: Expression pattern of the AP-1 family in
endometrial cancer: Correlations with cell cycle regulators. J
Cancer Res Clin Oncol. 127:545–550. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gong C, Shen J, Fang Z, Qiao L, Feng R,
Lin X and Li S: Abnormally expressed JunB transactivated by
IL-6/STAT3 signaling promotes uveal melanoma aggressiveness via
epithelial-mesenchymal transition. Biosci Rep. 38:BSR201805322018.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fan F, Bashari MH, Morelli E, Tonon G,
Malvestiti S, Vallet S, Jarahian M, Seckinger A, Hose D, Bakiri L,
et al: The AP-1 transcription factor JunB is essential for multiple
myeloma cell proliferation and drug resistance in the bone marrow
microenvironment. Leukemia. 31:1570–1581. 2017. View Article : Google Scholar
|
|
31
|
Sundqvist A, Morikawa M, Ren J, Vasilaki
E, Kawasaki N, Kobayashi M, Koinuma D, Aburatani H, Miyazono K,
Heldin CH, et al: JUNB governs a feed-forward network of TGFβ
signaling that aggravates breast cancer invasion. Nucleic Acids
Res. 46:1180–1195. 2018. View Article : Google Scholar
|
|
32
|
Sun Y, Wang J, Pan S, Yang T, Sun X, Wang
Y, Shi X, Zhao X, Guo J and Zhang X: LINC00657 played oncogenic
roles in esophageal squamous cell carcinoma by targeting miR-615-3p
and JunB. Biomed Pharmacother. 108:316–324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hyakusoku H, Sano D, Takahashi H, Hatano
T, Isono Y, Shimada S, Ito Y, Myers JN and Oridate N: JunB promotes
cell invasion, migration and distant metastasis of head and neck
squamous cell carcinoma. J Exp Clin Cancer Res. 35:62016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pei H, Guo Z, Wang Z, Dai Y, Zheng L, Zhu
L, Zhang J, Hu W, Nie J, Mao W, et al: RAC2 promotes abnormal
proliferation of quiescent cells by enhanced JUNB expression via
the MAL-SRF pathway. Cell Cycle. 17:1115–1123. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rao GN, Katki KA, Madamanchi NR, Wu Y and
Birrer MJ: JunB forms the majority of the AP-1 complex and is a
target for redox regulation by receptor tyrosine kinase and G
protein-coupled receptor agonists in smooth muscle cells. J Biol
Chem. 274:6003–6010. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kanno T, Kamba T, Yamasaki T, Shibasaki N,
Saito R, Terada N, Toda Y, Mikami Y, Inoue T, Kanematsu A, et al:
JunB promotes cell invasion and angiogenesis in VHL-defective renal
cell carcinoma. Oncogene. 31:3098–3110. 2012. View Article : Google Scholar
|
|
37
|
Rohini M, Haritha Menon A and Selvamurugan
N: Role of activating transcription factor 3 and its interacting
proteins under physiological and pathological conditions. Int J
Biol Macromol. 120:310–317. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen BP, Liang G, Whelan J and Hai T: ATF3
and ATF3 delta Zip. Transcriptional repression versus activation by
alternatively spliced isoforms. J Biol Chem. 269:15819–15826.
1994.PubMed/NCBI
|
|
39
|
Hashimoto Y, Zhang C, Kawauchi J, Imoto I,
Adachi MT, Inazawa J, Amagasa T, Hai T and Kitajima S: An
alternatively spliced isoform of transcriptional repressor ATF3 and
its induction by stress stimuli. Nucleic Acids Res. 30:2398–2406.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cai Y, Zhang C, Nawa T, Aso T, Tanaka M,
Oshiro S, Ichijo H and Kitajima S: Homocysteine-responsive ATF3
gene expression in human vascular endothelial cells: Activation of
c-Jun NH(2)-terminal kinase and promoter response element. Blood.
96:2140–2148. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li Y, Li Z, Zhang C, Li P, Wu Y, Wang C,
Bond Lau W, Ma XL and Du J: Cardiac Fibroblast-specific activating
transcription factor 3 protects against heart failure by
suppressing MAP2K3-p38 signaling. Circulation. 135:2041–2057. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nobori K, Ito H, Tamamori-Adachi M, Adachi
S, Ono Y, Kawauchi J, Kitajima S, Marumo F and Isobe M: ATF3
inhibits doxorubicin-induced apoptosis in cardiac myocytes: A novel
cardioprotective role of ATF3. J Mol Cell Cardiol. 34:1387–1397.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu X, Nguyen BC, Dziunycz P, Chang S,
Brooks Y, Lefort K, Hofbauer GF and Dotto GP: Opposing roles for
calcineurin and ATF3 in squamous skin cancer. Nature. 465:368–372.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yin X, Wolford CC, Chang YS, McConoughey
SJ, Ramsey SA, Aderem A and Hai T: ATF3, an adaptive-response gene,
enhances TGF{beta} signaling and cancer-initiating cell features in
breast cancer cells. J Cell Sci. 123:3558–3565. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu W, Iiizumi-Gairani M, Okuda H,
Kobayashi A, Watabe M, Pai SK, Pandey PR, Xing F, Fukuda K, Modur
V, et al: KAI1 gene is engaged in NDRG1 gene-mediated metastasis
suppression through the ATF3-NFkappaB complex in human prostate
cancer. J Biol Chem. 286:18949–18959. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ishiguro T, Nagawa H, Naito M and Tsuruo
T: Inhibitory effect of ATF3 antisense oligonucleotide on ectopic
growth of HT29 human colon cancer cells. Jpn J Cancer Res.
91:833–836. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ishiguro T, Nakajima M, Naito M, Muto T
and Tsuruo T: Identification of genes differentially expressed in
B16 murine melanoma sublines with different metastatic potentials.
Cancer Res. 56:875–879. 1996.PubMed/NCBI
|
|
48
|
Iyengar P, Combs TP, Shah SJ, Gouon-Evans
V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C,
Lisanti MP, et al: Adipocyte-secreted factors synergisti-cally
promote mammary tumorigenesis through induction of anti-apoptotic
transcriptional programs and proto-oncogene stabilization.
Oncogene. 22:6408–6423. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gargiulo G, Cesaroni M, Serresi M, de
Vries N, Hulsman D, Bruggeman SW, Lancini C and van Lohuizen M: In
vivo RNAi screen for BMI1 targets identifies TGF-beta/BMP-ER stress
pathways as key regulators of neural- and malignant glioma-stem
cell homeostasis. Cancer Cell. 23:660–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yuan X, Yu L, Li J, Xie G, Rong T, Zhang
L, Chen J, Meng Q, Irving AT, Wang D, et al: ATF3 suppresses
metastasis of bladder cancer by regulating gelsolin-mediated
remodeling of the actin cytoskeleton. Cancer Res. 73:3625–3637.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hackl C, Lang SA, Moser C, Mori A,
Fichtner-Feigl S, Hellerbrand C, Dietmeier W, Schlitt HJ, Geissler
EK and Stoeltzing O: Activating transcription factor-3 (ATF3)
functions as a tumor suppressor in colon cancer and is up-regulated
upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer.
10:6682010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jan YH, Tsai HY, Yang CJ, Huang MS, Yang
YF, Lai TC, Lee CH, Jeng YM, Huang CY, Su JL, et al: Adenylate
kinase-4 is a marker of poor clinical outcomes that promotes
metastasis of lung cancer by downregulating the transcription
factor ATF3. Cancer Res. 72:5119–5129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Bandyopadhyay S, Wang Y, Zhan R, Pai SK,
Watabe M, Iiizumi M, Furuta E, Mohinta S, Liu W, Hirota S, et al:
The tumor metastasis suppressor gene Drg-1 down-regulates the
expression of activating transcription factor 3 in prostate cancer.
Cancer Res. 66:11983–11990. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lu D, Wolfgang CD and Hai T: Activating
transcription factor 3, a stress-inducible gene, suppresses
Ras-stimulated tumorigenesis. J Biol Chem. 281:10473–10481. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Buganim Y, Madar S, Rais Y, Pomeraniec L,
Harel E, Solomon H, Kalo E, Goldstein I, Brosh R, Haimov O, et al:
Transcriptional activity of ATF3 in the stromal compartment of
tumors promotes cancer progression. Carcinogenesis. 32:1749–1757.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xie JJ, Xie YM, Chen B, Pan F, Guo JC,
Zhao Q, Shen JH, Wu ZY, Wu JY, Xu LY and Li EM: ATF3 functions as a
novel tumor suppressor with prognostic significance in esophageal
squamous cell carcinoma. Oncotarget. 5:8569–8582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gazon H, Barbeau B, Mesnard JM and
Peloponese JM Jr: Hijacking of the AP-1 signaling pathway during
development of ATL. Front Microbiol. 8:26862017. View Article : Google Scholar
|
